Literature DB >> 12238945

The development and use of quality-of-life measures to evaluate health outcomes in Japan.

Shunichi Fukuhara1, Naoki Ikegami, George W Torrance, Shuzo Nishimura, Michael Drummond, François Schubert.   

Abstract

Health outcomes measurement forms a key aspect of data collection for economic evaluations. Quality-of-life instruments provide a measure of patient-focused health outcomes. Such instruments, including the EuroQoL questionnaire (EQ-5D) and the Short-form 36 (SF-36) are already being used in Japan. Utility instruments provide an alternative way of measuring quality of life for use in economic analyses. At present, utility measurement in Japan is limited to scores derived from the EQ-5D. Although the SF-36 was designed as a health profile measure, it has since been tested for use as a utility measure, with valuation of items now being undertaken in Japan. Utility measurement in Japan is likely to be advanced further by the validation and introduction of the Health Utilities Index. The experiences of other countries provide the opportunity for Japan to learn how utility scores may be used in cost-utility analyses of healthcare technologies.

Entities:  

Mesh:

Year:  2002        PMID: 12238945     DOI: 10.2165/00019053-200220002-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Health-related quality of life among renal-transplant recipients in Japan.

Authors:  Y Tsuji-Hayashi; S Fukuhara; J Green; I Takai; T Shinzato; K Uchida; S Oshima; C Yamazaki; K Maeda
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

Review 2.  A review of the use of health status measures in economic evaluation.

Authors:  J Brazier; M Deverill; C Green; R Harper; A Booth
Journal:  Health Technol Assess       Date:  1999       Impact factor: 4.014

Review 3.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

4.  Estimating an EQ-5D population value set: the case of Japan.

Authors:  Aki Tsuchiya; Shunya Ikeda; Naoki Ikegami; Shuzo Nishimura; Ikuro Sakai; Takashi Fukuda; Chisato Hamashima; Akinori Hisashige; Makoto Tamura
Journal:  Health Econ       Date:  2002-06       Impact factor: 3.046

Review 5.  Information barriers to the implementation of economic evaluations in Japan.

Authors:  Shuzo Nishimura; George W Torrance; Naoki Ikegami; Shunichi Fukuhara; Michael Drummond; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Authors:  Naoki Ikegami; Michael Drummond; Shunichi Fukuhara; Shuzo Nishimura; George W Torrance; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan.

Authors:  S Fukuhara; S Bito; J Green; A Hsiao; K Kurokawa
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

Review 8.  Assigning values to intermediate health states for cost-utility analysis: theory and practice.

Authors:  B J Cohen
Journal:  Med Decis Making       Date:  1996 Oct-Dec       Impact factor: 2.583

Review 9.  Outcome measurement in economic evaluation.

Authors:  M Johannesson; B Jönsson; G Karlsson
Journal:  Health Econ       Date:  1996 Jul-Aug       Impact factor: 3.046

Review 10.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987
View more
  6 in total

1.  Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.

Authors:  Mitsuhiro Sado; Akihiro Koreki; Akira Ninomiya; Chika Kurata; Dai Mitsuda; Yasunori Sato; Toshiaki Kikuchi; Daisuke Fujisawa; Yutaka Ono; Masaru Mimura; Atsuo Nakagawa
Journal:  Psychiatry Clin Neurosci       Date:  2021-09-17       Impact factor: 12.145

2.  The water exercise improves health-related quality of life of frail elderly people at day service facility.

Authors:  Daisuke Sato; Koichi Kaneda; Hitoshi Wakabayashi; Takeo Nomura
Journal:  Qual Life Res       Date:  2007-10-20       Impact factor: 4.147

3.  Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): study protocol for a randomised clinical trial.

Authors:  Atsuo Nakagawa; Mitsuhiro Sado; Dai Mitsuda; Daisuke Fujisawa; Toshiaki Kikuchi; Takayuki Abe; Yuji Sato; Satoru Iwashita; Masaru Mimura; Yutaka Ono
Journal:  BMJ Open       Date:  2014-10-21       Impact factor: 2.692

4.  Neural and clinical changes of cognitive behavioural therapy versus talking control in patients with major depression: a study protocol for a randomised clinical trial.

Authors:  Nariko Katayama; Atsuo Nakagawa; Chika Kurata; Yohei Sasaki; Dai Mitsuda; Shigetsugu Nakao; Sayuri Mizuno; Mire Ozawa; Yuko Nakagawa; Natsumi Ishikawa; Satoshi Umeda; Yuri Terasawa; Hajime Tabuchi; Toshiaki Kikuchi; Takayuki Abe; Masaru Mimura
Journal:  BMJ Open       Date:  2020-02-25       Impact factor: 2.692

5.  A Randomized, Single-Blind, Placebo-Controlled Study on the Efficacy of the Arthrokinematic Approach-Hakata Method in Patients with Chronic Nonspecific Low Back Pain.

Authors:  Akira Kogure; Kazuhiko Kotani; Shigehiko Katada; Hiroshi Takagi; Masahiro Kamikozuru; Takashi Isaji; Setsuo Hakata
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

6.  Web-Based Cognitive Behavioral Therapy Blended With Face-to-Face Sessions for Major Depression: Randomized Controlled Trial.

Authors:  Shigetsugu Nakao; Atsuo Nakagawa; Yoshiyo Oguchi; Dai Mitsuda; Noriko Kato; Yuko Nakagawa; Noriko Tamura; Yuka Kudo; Takayuki Abe; Mitsunori Hiyama; Satoru Iwashita; Yutaka Ono; Masaru Mimura
Journal:  J Med Internet Res       Date:  2018-09-21       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.